Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2525163 | 0.84 | MAPK8 (0.56) | MAPK8BTKALDH1A1NPC1MAPK1 | |
| SCHEMBL3133230 | 0.82 | MCHR1 (0.55) | NOS3NOS2ALDH1A1NPC1MAPK1 | |
| SCHEMBL18578440 | 0.81 | MCHR1 (0.56) | NPC1MAPK1RAB9ANCF1MCHR1 | |
| SCHEMBL29545328 | 0.81 | MCHR1 (0.56) | NPC1MAPK1RAB9ANCF1MCHR1 | |
| SCHEMBL28004747 | 0.80 | NOS3 (0.42) | NOS3NOS2NCF1MCHR1ASIC3 | |
| SCHEMBL13498402 | 0.79 | NOS3 (0.40) | NOS3NOS2NCF1MCHR1ASIC3 | |
| SCHEMBL14896853 | 0.79 | NUDT1 (0.59) | NOS3NOS2NCF1MCHR1ASIC3 | |
| SCHEMBL1964751 | 0.79 | TSHR (0.41) | NOS3NOS2NCF1MCHR1TSHR | |
| SCHEMBL16511922 | 0.78 | BTK (0.65) | MAPK8BTKALDH1A1NPC1MAPK1 | |
| SCHEMBL2062738 | 0.77 | MCHR1 (0.40) | NOS3NOS2NCF1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482341-B2 | N-(pyridin-2-yl)-benzenesulfonamides; antidiabetic agents for Type II Diabetes; obesity; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-01-27 | — | — | US | claimed |
| WO-2006037501-A9 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | HOFFMANN LA ROCHE (CH) | 2007-08-02 | — | — | WO | claimed |
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | claimed |
| US-6949562-B2 | Heterocyclic compounds as ligands of the GABAA receptor | NEUROGEN CORPORATION (US) | 2005-09-27 | — | — | US | claimed |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| EP-1325006-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR | NEUROGEN CORPORATION (US) | 2003-07-09 | — | — | EP | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
| WO-2002012442-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR | NEUROGEN CORPORATION (US) | 2002-02-14 | — | — | WO | claimed |
| US-12516063-B2 | Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives for treating autoimmune diseases | ELI LILLY AND COMPANY (US) | 2026-01-06 | — | — | US | disclosed |
| WO-2025226545-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4103279-B1 | SUBSTITUTED 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES | LILLY CO ELI (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-115052660-B | Substituted 7- (methylamino) pyrazolo [1,5-a ] pyrimidine-3-carboxamide derivatives | 伊莱利利公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230136885-A1 | SUBSTITUTED 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES | ELI LILLY AND COMPANY | 2023-05-04 | — | — | US | disclosed |
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-03-23 | — | — | US | disclosed |
| EP-0705260-A1 | CONDENSED 4-AMINOPYRIDINES WITH ANTIRHEUMATIC ACTIVITY | KNOLL AKTIENGESELLSCHAFT (DE) | 1996-04-10 | — | — | EP | disclosed |
| US-5464781-A | TREATING RHEUMATIC DISEASES | THE BOOTS COMPANY PLC (GB) | 1995-11-07 | — | — | US | disclosed |
| WO-1995000511-A1 | CONDENSED 4-AMINOPYRIDINES WITH ANTIRHEUMATIC ACTIVITY | KNOLL AG (DE) | 1995-01-05 | — | — | WO | disclosed |
| CN-1096784-A | Therapeutic agents containing substituted 4(5) -amino-1, 8-diaminonaphthalenes | BOOTS CO PLC (GB) | 1994-12-28 | — | — | CN | disclosed |
| EP-0618916-A1 | ANTI-RHEUMATIC NAPHTHYRIDINE DERIVATIVES | Knoll AG (DE) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993013097-A1 | ANTI-RHEUMATIC NAPHTHYRIDINE DERIVATIVES | THE BOOTS COMPANY PLC (GB) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | MAPK8 3728/4885BTK 2072/4885NOS3 3846/4885 |
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HSD3B1, HSD3B2, HSD11B2 | MAPK8 4091/4885BTK 3747/4885NOS3 1084/4885 |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | MAPK8 3728/4885BTK 2072/4885NOS3 3846/4885 |
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK2, IRAK1 | MAPK8 632/4885BTK 15/4885NOS3 3140/4885 |
| US-20230136885-A1 | SUBSTITUTED 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES | SSB, IL1R1, SLC5A1 | MAPK8 291/4885BTK 541/4885NOS3 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.